Filing Details

Accession Number:
0000899243-17-007445
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-14 16:14:57
Reporting Period:
2017-03-13
Filing Date:
2017-03-14
Accepted Time:
2017-03-14 16:14:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
885590 Valeant Pharmaceuticals International Inc. VRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1056513 A William Ackman 888 Seventh Avenue
42Nd Floor
New York NY 10019
Yes No No No
1336477 Ps Management Gp, Llc 888 Seventh Avenue
42Nd Floor
New York NY 10019
Yes No No No
1336528 Pershing Square Capital Management, L.p. 888 Seventh Avenue, 42Nd Floor
New York NY 10019
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, No Par Value Disposition 2017-03-13 18,114,432 $11.00 0 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Call Option (call equivalent position) Disposition 2017-03-14 91,200 $0.30 9,120,000 $60.00
Common Stock Put Option (call equivalent position) Disposition 2017-03-13 9,120,000 $47.65 9,120,000 $60.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-01-18 No 4 S Indirect
0 2019-01-18 No 4 P Indirect
Footnotes
  1. In addition to Pershing Square Capital Management, L.P., a Delaware limited partnership ("Pershing Square"), this Form 4 is being filed jointly by PS Management GP, LLC, a Delaware limited liability company ("PS Management"), and William A. Ackman, a citizen of the United States of America (collectively, the "Reporting Persons"), each of whom has the same business address as Pershing Square and may be deemed to have a pecuniary interest in securities reported on this Form 4 (the "Subject Securities").
  2. Pershing Square advises the accounts of Pershing Square, L.P., a Delaware limited partnership ("PS"), Pershing Square II, L.P., a Delaware limited partnership ("PS II"), Pershing Square International, Ltd., a Cayman Islands exempted company ("PS International"), and Pershing Square Holdings, Ltd., a limited liability company incorporated in Guernsey ("PSH" and together with PS, PS II and PS International, the "Pershing Square Funds").
  3. Pershing Square, as the investment adviser to the Pershing Square Funds, may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934. As the general partner of Pershing Square, PS Management may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a). By virtue of William A. Ackman's position as Chief Executive Officer of Pershing Square and managing member of PS Management, William A. Ackman may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a). Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
  4. William A. Ackman and Stephen Fraidin, each a member of the board of directors of the Issuer, were elected to the board as representatives of the Reporting Persons, the Pershing Square Funds and Pershing Square GP, LLC. As a result, each of those persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934
  5. The Reporting Persons for the accounts of the Pershing Square Funds unwound listed American-style call options (with 100 multiplier) and unwound over-the-counter European-style put options, each referencing a total of 9,120,000 shares of the Issuer's common stock which had an expiration date of January 18, 2019.